Jörg Stockhaus

Fondatore presso conoGenetix biosciences GmbH

Consumer Services

Process Industries

Health Technology

Profilo

Jörg Stockhaus is the founder of conoGenetix biosciences GmbH, which was founded in 2002, where he holds the title of Senior Scientist.
Currently, he is a Fellow at The Rockefeller University.
In the past, he held the position of Principal at Aventis Cropscience and Heinrich-Heine-Universität Düsseldorf.

Posizioni attive di Jörg Stockhaus

Società	Posizione	Inizio
conoGenetix biosciences GmbH conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.	Fondatore	01/03/2002
The Rockefeller University	Corporate Officer/Principal	-

Tutte le posizioni attive di Jörg Stockhaus

Precedenti posizioni note di Jörg Stockhaus

Società	Posizione	Fine
Aventis Cropscience	Corporate Officer/Principal	-
Heinrich-Heine-Universität Düsseldorf	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Jörg Stockhaus

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jörg Stockhaus

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Aventis Cropscience	Process Industries
conoGenetix biosciences GmbH conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.	Health Technology